Clinical Trial

A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 13, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-06-28; most recent amendment 2024-12-10.
Status change: Not Yet Recruiting → Recruiting 2024-02-21
Trial Details
NCT Number NCT05934513
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment 95 participants
Start Date 2023-09-06
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-13